Management of sexual dysfunction due to antipsychotic drug therapy
- 14 November 2012
- journal article
- review article
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2012 (11) , CD003546
Abstract
Psychotropic drugs are associated with sexual dysfunction. Symptoms may concern penile erection, lubrication, orgasm, libido, retrograde ejaculation, sexual arousal, or overall sexual satisfaction. These are major aspects of tolerability and can highly affect patients' compliance. To determine the effects of different strategies (e.g. dose reduction, drug holidays, adjunctive medication, switching to another drug) for treatment of sexual dysfunction due to antipsychotic therapy. An updated search was performed in the Cochrane Schizophrenia Group's Trials Register (3 May 2012) and the references of all identified studies for further trials. We included all relevant randomised controlled trials involving people with schizophrenia and sexual dysfunction. We extracted data independently. For dichotomous data we calculated random effects risk ratios (RR) with 95% confidence intervals (CI), for crossover trials we calculated Odds Ratios (OR) with 95% CI. For continuous data, we calculated mean differences (MD) on the basis of a random-effects model. We analysed cross-over trials under consideration of correlation of paired measures. Currently this review includes four pioneering studies (total n = 138 , duration two weeks to four months), two of which are cross-over trials. One trial reported significantly more erections sufficient for penetration when receiving sildenafil compared with when receiving placebo (n = 32, MD 3.20 95% CI 1.83 to 4.57), a greater mean duration of erections (n = 32, MD 1.18 95% CI 0.52 to 1.84) and frequency of satisfactory intercourse (n = 32, MD 2.84 95% CI 1.61 to 4.07). The second trial found no evidence for selegiline as symptomatic treatment for antipsychotic-induced sexual dysfunction compared with placebo (n = 10, MD change on Aizenberg's sexual functioning scale -0.40 95% CI -3.95 to 3.15). No evidence was found for switching to quetiapine from risperidone to improve sexual functioning (n = 36, MD -2.02 95% CI -5.79 to 1.75). One trial reported significant improvement in sexual functioning when participants switched from risperidone or an typical antipsychotic to olanzapine (n = 54, MD -0.80 95% CI -1.55 to -0.05). We are not confident that cross-over studies are appropriate for this participant group as they are best for conditions that are stable and for interventions with no physiological and psychological carry-over. Sildenafil may be a useful option in the treatment of antipsychotic-induced sexual dysfunction in men with schizophrenia, but this conclusion is based only on one small short trial. Switching to olanzapine may improve sexual functioning in men and women, but the trial assessing this was a small, open label trial. Further well designed randomised control trials that are blinded and well conducted and reported, which investigate the effects of dose reduction, drug holidays, symptomatic therapy and switching antipsychotic on sexual function in people with antipsychotic-induced sexual dysfunction are urgently needed.Keywords
This publication has 94 references indexed in Scilit:
- Sexual dysfunction in people with schizophreniaMental Health Practice, 2012
- Second Generation Antipsychotics Improve Sexual Dysfunction in Schizophrenia: A Randomised Controlled TrialSchizophrenia Research and Treatment, 2011
- The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)BMC Psychiatry, 2008
- Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF?Schizophrenia Bulletin, 2006
- Measuring inconsistency in meta-analysesBMJ, 2003
- Psychotropic Drug???Induced Sexual Function DisordersDrug Safety, 1998
- Low-Dose imipramine for thioridazineinduced male orgasmic disorderJournal of Sex & Marital Therapy, 1996
- Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trialsJAMA, 1995
- Bias in Treatment Assignment in Controlled Clinical TrialsNew England Journal of Medicine, 1983
- Sexual dysfunction in women using major tranquilizersPsychosomatics, 1982